MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of “Hold” from Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX) has received a consensus recommendation of “Hold” from the sixteen analysts that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $23.0769.

Several brokerages recently issued reports on MLTX. Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $12.00 to $40.00 in a research note on Thursday, March 19th. Wolfe Research upgraded MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and boosted their price target for the company from $12.00 to $24.00 in a research note on Monday, March 23rd. Needham & Company LLC boosted their price target on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. The Goldman Sachs Group lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and upped their price objective for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. Finally, Oppenheimer upped their price objective on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total value of $62,962,500.00. Following the sale, the director directly owned 1,039,238 shares in the company, valued at approximately $17,448,806.02. This represents a 78.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 12.02% of the company’s stock.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Large investors have recently modified their holdings of the stock. Principal Financial Group Inc. bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $509,000. Rhenman & Partners Asset Management AB grew its stake in shares of MoonLake Immunotherapeutics by 360.0% in the 3rd quarter. Rhenman & Partners Asset Management AB now owns 207,000 shares of the company’s stock valued at $1,484,000 after purchasing an additional 162,000 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of MoonLake Immunotherapeutics by 22,387.5% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 84,553 shares of the company’s stock valued at $606,000 after purchasing an additional 84,177 shares during the period. Boxer Capital Management LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $1,792,000. Finally, SG Americas Securities LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $126,000. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Trading Down 2.2%

Shares of MLTX opened at $16.98 on Tuesday. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -4.82 and a beta of 1.19. The stock’s 50-day moving average price is $17.00 and its 200 day moving average price is $15.87.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.92). During the same period in the prior year, the business earned ($0.72) EPS. As a group, research analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.